ORION CORP.B UNSP.ADR 1/2 (F:OFK0) — Market Cap & Net Worth
Market Cap & Net Worth: ORION CORP.B UNSP.ADR 1/2 (OFK0)
ORION CORP.B UNSP.ADR 1/2 (F:OFK0) has a market capitalization of $8.31 Billion (€7.10 Billion) as of April 27, 2026. Listed on the F stock exchange, this Germany-based company holds position #2556 globally and #519 in its home market, demonstrating a -0.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ORION CORP.B UNSP.ADR 1/2's stock price €36.20 by its total outstanding shares 217703034 (217.70 Million).
ORION CORP.B UNSP.ADR 1/2 Market Cap History: 2021 to 2026
ORION CORP.B UNSP.ADR 1/2's market capitalization history from 2021 to 2026. Data shows growth from $3.87 Billion to $8.76 Billion (20.79% CAGR).
ORION CORP.B UNSP.ADR 1/2 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ORION CORP.B UNSP.ADR 1/2's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of OFK0 by Market Capitalization
Companies near ORION CORP.B UNSP.ADR 1/2 in the global market cap rankings as of April 27, 2026.
Key companies related to ORION CORP.B UNSP.ADR 1/2 by market ranking:
- Eli Lilly and Company (SA:LILY34): Ranked #16 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
- Eli Lilly and Company (NYSE:LLY): Ranked #18 globally with a market cap of $791.16 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #22 globally with a market cap of $548.11 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #39 globally with a market cap of $351.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #16 | Eli Lilly and Company | SA:LILY34 | $853.51 Billion | R$153.70 |
| #18 | Eli Lilly and Company | NYSE:LLY | $791.16 Billion | $883.96 |
| #22 | Johnson & Johnson | NYSE:JNJ | $548.11 Billion | $227.50 |
| #39 | AbbVie Inc | NYSE:ABBV | $351.35 Billion | $198.71 |
ORION CORP.B UNSP.ADR 1/2 Historical Marketcap From 2021 to 2026
Between 2021 and today, ORION CORP.B UNSP.ADR 1/2's market cap moved from $3.87 Billion to $ 8.76 Billion, with a yearly change of 20.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €8.76 Billion | +8.86% |
| 2025 | €8.04 Billion | +51.92% |
| 2024 | €5.29 Billion | +15.83% |
| 2023 | €4.57 Billion | -22.14% |
| 2022 | €5.87 Billion | +51.71% |
| 2021 | €3.87 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of ORION CORP.B UNSP.ADR 1/2 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.31 Billion USD |
| MoneyControl | $8.31 Billion USD |
| MarketWatch | $8.31 Billion USD |
| marketcap.company | $8.31 Billion USD |
| Reuters | $8.31 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ORION CORP.B UNSP.ADR 1/2
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflam… Read more